Prerpints.org logo
Preprint
Article

Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline-1,2, 3-Triazole-Anilines as Potential Antitubercular and Anti-HIV Agents

This version is not peer-reviewed.

Submitted:

10 April 2025

Posted:

11 April 2025

You are already at the latest version

Abstract
HIV/AIDS and Mycobacterial tuberculosis (Mtb) are the leading cause of deaths world-wide. Thus, better medicaments are required to manage these diseases. Quinolines have shown great potential due to their broad spectrum of biological activity. Thus, quinoline-1,2,3-triazole-aniline hybrids were synthesised in moderate to good yields. Compounds 11g (IC50 = 0.388 µM), 11h (IC50 = 0.01032 µM) and 11i (IC50 = 0.167 µM) ex-hibited the most promising in vitro activities against the wild-type HIV-1 subtype B, with 11h being 9-fold more active than AZT (IC50 = 0.0909 µM), the reference drug. Fur-thermore, compound 11h displayed moderate activity with MIC90 of 88μM against Mtb’s H37Rv strain. Cytotoxicity studies on TMZ-bl-cell lines revealed that most of the tested compounds were generally non-cytotoxic; the selectivity index (SI) for 11h, the front runner, is > 2472. Molecular docking studies revealed that 11h interacted with Phe112, Tyr108, Glu283, and Trp86 amino acid residues in the active site of the HIV-1. DFT studies revealed that 11h has the ability to donate and accept electrons to and from available orbitals. The predicted ADMET studies showed that these compounds pos-sess drug-likeness, and 11h has the potential to be further optimisation as anti-HIV-1 agent.
Keywords: 
quinoline-1
;  
2
;  
3-triazole-anilines
;  
click reaction
;  
HIV-1 subtype B
;  
molecular docking
;  
density functional theory
Subject: 
Chemistry and Materials Science  -   Medicinal Chemistry

supplementary.pdf (1.55MB )

1. Introduction

Africa and other developing countries have borne a substantial burden of mortality attributed to infectious diseases [1,2]. One of the most concerning infectious diseases, Tuberculosis (TB), is caused by Mycobacterium tuberculosis (Mtb), a gram-negative bacterium with a lipid-rich outer membrane that makes it resilient against various antibiotics [3,4,5]. To treat drug-susceptible TB, combinations of isoniazid, rifampicin, pyrazinamide, and ethambutol, termed first-line drugs, are administered [6,7,8]. Each of these drugs targets specific areas in Mtb with the shared objective of inhibiting the production of essential biological processes critical for bacterial replication and survival [6]. Over the years, due to the gene mutations, Mtb has evolved to more resistant isoforms, such as multi-drug resistant (MDR-TB), extensively drug-resistant (XDR-TB) and totally drug-resistant TB (TDR-TB) [9,10].
On the other hand, the human immunodeficiency virus (HIV) remains one of the most prevalent infectious diseases [11]. To date, 39.9 million people are living with HIV/AIDS (PLWH) worldwide [12]. Effective drug development over the years has saved many lives, with the discovery of the Highly active antiretroviral therapy (HAART) being the pivotal moment. The use of antiretroviral drugs has decreased the morbidity and mortality rate of PLWH by turning HIV-1 into a chronic and manageable disease [13,14]. Despite HAART’s early success, drug-resistant mutant development rendered it less effective over time. HIV is a complex virus with a high mutation rate, considering it replicates in several replication stages. Antiretroviral drugs target different stages of the HIV-1 life cycle: viral attachment, reverse transcription, integration, proteolysis and viral budding [15]. There are seven classes of antiretrovirals based on their molecular mechanisms and resistance profiles, namely: nucleoside-analogue reverse transcriptase inhibitors (NNRTIs), non–nucleoside reverse transcriptase inhibitors (NNRTIs), integrase inhibitors, protease inhibitors (PIs), fusion inhibitors, post-attachment inhibitor (PAI) and co-receptor antagonists [16,17,18,19]. These drug regimens constantly evolve, and new drugs are continually being developed in each class.
Various quinoline- and/or 1,2,3-triazole-containing compounds have been reported to show promising activities against either Mtb [20,21,22,23,24,25,26,27,28] or HIV infections [29,30,31,32], with some already in clinical settings, including the 1,2,3 triazole-pyrimidine hybrids that are now part of the second generation NNRTI’s [30]. Bedaquiline (or TMC-207) (Figure 1), a quinoline-based compound, is clinically utilised for treating multidrug-resistant TB [33]. This compound binds to the subunit C of mycobacterial ATP synthase, an essential enzyme for Mtb energy production and survival. However, bedaquiline suffers from several side effects due to its potent inhibition of the potassium ether-ago-go-related gene (hERG) that could potentially lead to cardiac arrest [34]. Thus, new quinoline-based anti-Mtb agents, devoid of bedaquiline’s shortcomings, are critically important. Due to the broad spectrum of activities, various quinoline-triazole hybrids have shown promise over the years. Thomas et al. [21] reported on a series of new 6-methoxyquinoline triazole amides (1) (MIC = 0.625 µg/ml), sulphonamides (2) (MIC = 0.625 µg/ml), and amidopiperazines (3) (MIC = 0.625 µg/ml) that exhibited promising antitubercular activities. Our group recently disclosed a series of 7-chloroquinoline-triazole-benzimidazole hybrids that demonstrated excellent Mtb activity, with isomeric mixture 4 showing MIC90 of 1.49 µM [22]. Previously, Costa et al. [29] reported several quinoline-1,2,3-triazole hybrids, such as 5 (IC50 = 800 nm), that showed promising activity against HIV reverse transcriptase. Maraviroc, the first licensed CCR5 co-receptor antagonist containing the triazole moiety, is used to treat HIV infections and is less prone to drug resistance than the presently used ([N]NRTI) [35,36,37].
Simultaneously targeting TB and HIV is of paramount importance, especially considering the high prevalence of co-infection, drug resistance and the potential for drug-drug interactions in patients receiving treatment for both diseases [38]. Combining quinoline and triazole scaffolds into hybrid structures may synergistically improve efficacy against both Mtb and HIV [39,40]. The structural analysis of some of the compounds shown in Figure 1 reveals common structural features, shown in blue in Figure 2. Could these structural features be responsible for these compounds combined anti-Mtb and anti-HIV activities? Thus, in this study, we report on the synthesis, biological evaluation and computational studies of a series of compounds containing these structural features, albeit with the substitution of the quinoline moiety limited to the 7-chloro only.

2. Results and Discussion

2.1. Chemistry

The target compounds were synthesised in two stages, as shown in Scheme 1. The first stage is the formation of the two key intermediates, namely the 7-chloroquinoline-4-azide 7 and the alkyne 10a-j, via steps 1 and 2. These intermediates are then subjected to “Click chemistry” [27] in step 3 to yield the final quinoline-1,2,3, triazole-aniline derivatives, 11a-j, in 43 to 92% yields (Table 1). 1D and 2D nuclear magnetic resonance (NMR) and infrared (IR) spectroscopy were used to confirm the structures, while mass spectrometry confirmed the masses of the desired products (see supplementary information).
Confirmation of the 1,2,3-triazole formation was achieved by observing the chemical shift of the singlet triazole methine proton, which appears in the aromatic region around δH 8.7 ppm. Secondly, the methylene doublet, due to coupling with the neighbouring NH, appears as expected at around 4.47 ppm, while the NH appears as a triplet at 6.21 ppm. All the quinoline protons are appearing as expected. The 13C NMR ATP NMR analysis also confirmed the formation of the hybrid, with the critical methine and methylene resonances appearing at 125.68 and 38.95 ppm, respectively.
The heteronuclear multiple bond correlations (HMBC) experiment (Figure 3) further validated the triazole ring formation, with close correlations of H6-C13, H1-C13, H1-C6 and H6-C14 being observed and shown in the structure of 11a. The mass spectrometry confirmed the masses of the target compounds based on their main or major fragment as observed in the base peak. All the other compounds were characterized in a similar manner.

2.2. In Vitro Biological Activities

The synthesised quinoline-1,2,3-triazole anilines were evaluated in vitro against Mtb H37Rv (ATCC 27294) strain, against HIV-1 subtype B, and their cytotoxicity assessed using MTT assay on TZM-bl cell-line (Table 2). The Mtb activity is represented as the 90% minimum inhibitory concentration (MIC90), while HIV and cytotoxicity are represented as the 50% inhibitory concentration (IC50) and 50% cytotoxicity concentration (CC50), respectively. In terms of anti-Mtb, the data reveals that all the synthesised hybrid compounds did not show any appreciable activity, with compounds 11b, 11c, 11i and 11j exhibiting poor activity (MIC90 > 1000 μM), while 11a, 11d-g, and 11i fell within the range of 100-200 μM. Notably, compound 11h exhibited the most potent activity with MIC90 of 88μM, distinguishing it as the most active among all these, albeit 9-fold less active than the reference drug, ethambutol.
Against HIV-1, initially, all the compounds showed > 50% inhibition in primary inhibition assay were progressed to determine their IC50, and azidothymidine (AZT) was used as a control drug. Generally, all the compounds inhibited the growth of the HIV-1 subtype B virus, ranging from 58-100% inhibition potential (see percentage cell viability plots in the supplementary information). The IC50 values for most of these compounds were moderate, with only three compounds exhibiting sub-micromolar activity, namely 11g, 11h and 11i, albeit not as active as AZT. Compound 11g (consisting of the trifluoromethyl substituent on the phenyl ring) (IC50 = 0.3883 µM) and 11i (the 3-nitrosubstituted) (IC50 = 0.170 µM) were 4- and 1.8-fold less active than AZT, respectively. On the other hand, 11h (the 3-flourosubstituted) (IC50 = 0.01032 µM) is 8.8 times more potent than AZT. Interestingly, compound 11h was also the most active against Mtb, highlighting its dual active potential. Cytotoxicity assessment revealed that five of the synthesised compounds, 11a, 11c-e and 11g, exhibited CC50 >100 µM, with 11g showing the best cytotoxicity profile with CC50 = 4414 µM and selectivity index (SI) of > 11300, which is not far off from that of AZT (SI = 12349). On the other hand, the CC50 value of compound 11h was 25.52 µM and its SI > 2400, an indication of the less likely to be cytotoxic in vivo [41,42]. Thus, compound 11h is a potential “hit” compound for further optimisation as a potential anti-HIV agent based on its activity and cytotoxicity profile.

2.3. In Silico Studies

2.3.1. Molecular Docking

To validate the observed biological activities, all hybrid compounds underwent in silico docking simulations into the active site of the Mtb ATP synthase enzyme (PDB ID: 4VIF) [43] and the antiviral enzyme (PDB ID: 4MBS) [44] using the Maestro software in Schrödinger Suite [45]. Docking scores recorded in Table 3 ranged from -2.879 to -2.035 kcal/mol for the antimicrobial target and -7.371 to -4.815 kcal/mol for the antiviral target. Compound 11d had the best docking score, followed by 11e and 11h against the antiviral enzyme, while 11e had the best docking score against the antimicrobial ATP synthase, followed by 11g and 11h. Notably, the docking scores were lower for the TB target than for the HIV target, consistent with the obtained biological data. The two promising compounds in the anti-TB and anti-HIV biological screenings, and their interaction with the active sites of the proteins were observed, as depicted in Figure 4.
The 4V1F enzyme is known to be the target for compounds containing the quinoline moiety, such as mefloquine and bedaquiline, and has been used extensively in molecular docking of quinoline-based compounds [22,43]. Compound 11h (MIC90 = 88.72 µM) displayed a docking score of -2.606 compared to 11a (MIC90 = 186.52 µM), which had a docking score of -2.540. In Figure 4, compound 11a demonstrated hydrogen bond interactions with Glu65, Tyr68, and Phe69 and additional interactions with Ala66, Gly62, Val61, and Phe58 amino acid residues. On the other hand, 11h exhibited similar interactions with amino acid residues but without any visible hydrogen interaction. Other biological properties of 11h may contribute further to its biological activity.
The selected CCR5 chemokine receptor acts as a co-receptor for HIV-1 viral entry and its associated enzyme (4MBS) is a known target for maraviroc, a triazole-containing antiretroviral [36]. Furthermore, Singh et al. [46] and Ibrahim et al. [47] reported quinoline-based compounds as chemokine receptor CCR5 inhibitors. Compound 11h (IC50 = 0.01032 µM) demonstrated a significantly higher docking score of -7.362 than 11a (IC50 = 3.013 µM). Hydrogen bonding interactions were observed with various amino acid residues in the active sites; the quinoline and aniline moieties interacted with Phe112, Tyr108, Glu283, and Trp86 for 11h and 11a. Further interactions with Tyr89 and Trp248 amino acid residues are observed for both compounds.

2.3.2. Density Functional Theory Studies

The stability of a compound is a consequence of its orbital energies [48]. Table 4 shows the stability and/or reactivity indices of 11h at DFT/B3LYP/6-311++G(d,p) level of theory. These reactivity indices are vital for molecular reactivity. The ionisation potential (I) and the electron affinity (A) of 11h were 5.89 eV and 2.64 eV, respectively. A low I value suggests that a molecule can give up electrons readily [49]. A high value of A implies a good electron-accepting potential for the molecules [49]. The energy gap (Eg) is derived as a difference between the frontier orbital energies. The Eg of 11h was 3.25 eV, while its chemical hardness was 1.63 eV. The global softness was 0.615 eV-1. The ability of a molecule to attract an electron is related to the electronegativity, χ. The χ of 11h was 4.27 eV, while its electrophilicity was 5.59 eV. The values of the reactivity descriptors in 11h here are close to reported bioactive compounds at the same level of theory [50]. Compound 11h can give up electrons easily and also accept electrons from the values of its ionisation potential and electron affinity.
HOMO, LUMO and ESP surface maps of 11h
The optimised structure, HOMO, LUMO and electrostatic potential maps of 11h are shown in Figure 5. The HOMO map of the compound was spread across the entire fluoroaniline moiety, while the LUMO was delocalised over the other side of the compound (quinoline and triazole rings). This indicates that the compound has the ability to act as an electron donor as well as an acceptor of electrons.
The electrostatic potential (ESP) map (Figure 6) accounts for the regions in a molecule prone to nucleophilic and electrophilic attacks. While the red- and yellow-mapped regions show negative electrostatic potential and are prone to attack by an electrophile, the blue- and/or green-mapped regions indicate positive electrostatic potential and are prone to nucleophilic attack.
The sites prone to electrophilic attack in 11h are the fluorine and chlorine atoms, as well as the quinoline nitrogen. The sites prone to nucleophilic attack are the triazole’s C19, C23, N21, N22 and H30 atoms, extending to N18 through C24 and their hydrogen atoms; some faint blue/green maps were seen on other parts of the quinoline rings. The charge separation between these two opposite electrostatic potential sites could facilitate intramolecular charge transfer [51].

2.3.3. ADMET Predictions

Adsorption, distribution, metabolism, excretion and toxicity (ADMET) properties describe a drug's absorption, distribution, metabolism, excretion and toxicity within living organisms [52]. ADMET predictions of the synthesised 1,2,3-triazole-quinoline-aniline compounds were calculated using the QikProp utility in the Schrödinger Suite [45]. The human serum binding ability coefficient (QPlogKhsa) ranged from 0.500 to 0.779, suggesting likely favourable bioavailability and less likely to be protein-bound. The predicted aqueous solubility (QPlogS) values for all but one compound, 11g (-6.979), were within the acceptable range, suggesting good intestinal absorption.
The predicted percentage of human oral absorption for most compounds was 100%, except for 11i, which has ~88%, indicating potential excellent oral bioavailability, with >80% being categorised as high. Furthermore, the predicted brain/blood coefficient (QPlogBB) values were also in the accepted range (-0.023 to -1.346), while these compounds were predicted to be likely inactive in the central nervous system (CNS) (< +2). The likely number of metabolic reactions from the cytochrome P450 enzyme was predicted to be less than 7, indicating a favourable outcome. Lastly, most of these compounds adhered to Lipinski's criteria for molecular weight, octanol-water coefficient, and the number of hydrogen bond donors and acceptors, except 11c and 11g, which violated this guideline due to their high lipophilicity (clogP) of greater than 5.

3. Materials and Methods

3.1. Chemistry

All the Chemical reagents used in the synthesis were purchased from Merck South Africa/Sigma Aldrich and I&A Chemicals, with purity ranging from 97-100%. HPLC grade and crude solvents were used. The reaction progress was monitored using a thin layer chromatography (TLC) analysis on aluminium-backed TLC plates (Kiese gel 60 F254 plates, Merck South Africa) and visualised under ultraviolet light (254 nm wavelength) All the synthesised final compounds and some intermediates were purified using the flash-column chromatography on silica gel (0.063-0.200mm) and various solvent systems. Melting point analysis was conducted using an electrothermal IA9100 melting point apparatus on the solid compounds using glass capillary tubes; melting points are recorded in ℃ and are uncorrected. Final compounds and intermediates’ functional groups were analysed and confirmed by Fourier Transform Infrared (FTIR) spectroscopy on the Perkin Elmer 100 spectrophotometer with Universal ATR sampling accessory; wavenumbers (ʋ) on the spectra expressed in cm-1.
Nuclear magnetic resonance (NMR) analysis was conducted on the Bruker Avance III 600 Hz spectrometer using deuterated chloroform (CDCl3) and dimethylsulfoxide (DMSO-d6) and solvents. Topspin was used for spectra analysis; coupling constants (J) were reported in Hertz (Hz) and the chemical shifts in parts per million (ppm) using tetramethyl silane (TMS) peak as reference. The splitting patterns are reported as singlet (s), doublet (d), multiplet (m), triplet (t), quartet (q), doublet of doublets (dd), doublet of triplets (dt), or triplet of doublets (td). The solvent peaks were referenced at 2.50 (1H) and δ 39.5 (13C) for DMSO-d6, and 7.26 (1H) and 77.0 (13C) for CDCl3, while residual water was observed at 3.35 and 1.56 ppm, respectively.
Preparation of N-[1-(7-chloroquinolin-4-yl)-1H-1,2,3-triazol-4-yl]anilines (11a-j)
100 mg (0,77 mmol) of the respective N-(prop-2-ny-l-yl)anilines (10a-j) and 189 mg (0.92mmol) 7-chloroquinoline-4-azide (7) were dissolved in 10mL DCM in a 100 mL round bottom flask. Thereafter, 22% sodium ascorbate, 10% copper sulphate and 10mL of water were added, and the reaction mixture was vigorously stirred at room temperature until completion (24 hrs). On completion, based on TLC, 100mL of water was added, followed by 5 x 40mL DCM extraction, and the combined extracts evaporated in vacuo to afford crude compounds, which were purified by column chromatography (DCM: MeOH; 95:5%):
1-(7-Chloro-4-quinolinyl)-1H-1,2,3,-triazole-4-methanamine (11a): As a cream white solid, yield 88%, mp 15-152℃, IR (cm-1) C-H 2900-3000, 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.47 (2H, d, J = 5.7 Hz, H-1), 6.21 (1H, t, J = 5.7 Hz, H-2), 6.58 (1H, t, J = 7.5 Hz, H-5), 6.72 (2H, d, J = 7.9 Hz, H-3 and H-3’), 7.11 (2H, dd, J1 = 8.3 Hz, J2 = 7,4 Hz, H-4 and H-4’), 7.78 (1H, dd, J1=7.0 Hz, J2= 2 Hz, H-10), 7.8 (1H, d, J = 4.5 Hz, H-7), 8.02 (1H, d, J = 9.1 Hz, H-11), 8.28 (1H, d, J = 2.0 Hz, H-9), 8.74 (1H, s, H-6), 9.14 (1H, d, J = 4.5 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.9 (C-1), 112.9 (C-3), 116.7 (C-5), 117.3 (C-7), 120.7 (C-15a), 125.7 (C-11), 125.9 (C-6), 128.6 (C-9), 129.4 (C-4,10), 135.8 (C-16), 140.9 (C-14), 147.1 (C-13), 148.7 (C-12), 149.9 (C-15b), 152.8 (C-8). TOFF MS ES-: (m/z) 306.0968 (100%) [(M-H) - N2]- (Calculated for C18H13ClN3-(306.0803)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-4-bromoaniline (11b): As a light brown solid, yield 87%, mp 187-190 ℃ , IR (cm-1) C-H 2900-3000; 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.48 (2H, d, J = 5.2 Hz, H-1), 6.4 (1H, s, H-2), 6.71 (2H, d, J = 8.7 Hz, H-4), 7.25 (2H, d, J =8.7 Hz, H-3), 7.76 (1H, dd, J1 = 9.0, J2 = 1.5 Hz, H-10), 7.81 (1H, d, J = 4.6 Hz, H-7), 8.01 (1H, d, J = 9.0 Hz, H-11), 8.26 (1H, d, J = 1.5 Hz, H-9), 8.74 (1H, s, H-6), 9.14 (1H, d, J = 4.5 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 38.0 (C-1)114.0 (C-4), 131.0 (C-3), 117.3 (C-7), 120.7 (C-15a), 125.6 (C-6), 125.8 (C-11), 128.6 (C-9), 129.4 (C-10), 135.8 (C-16), 140.9 (C-14), 148.0 (C-12), 147.0 (C-13), 149.8 (C-15b), 152.0 (C-8), 107.0 (C-5). TOF MSMS ES-: (m/z) 451.4776 [(M- + HCl]- [Calculated for C18H19BrCl2N5 (451.1490)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-4-iodoaniline (11c): As a brown solid, yield 92%, mp 195-199 ℃ , IR (cm-1) C-H 2900-; 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.45 (2H, d, J =5.5 Hz, H-1), 6.47 (1H, t, J = 5.5 Hz, H-2), 6.58 (2H, d, J = 8.7 Hz, H-4), 7.37 (2H, d, J = 8.7 Hz, H-3), 7.78 (1H, dd, J1 = 9.0, J2 = 1.9 Hz, H-10), 7.81 (1H, d, J = 4.5 Hz, H-7), 7.99 (1H, d, J = 8.8 Hz, H-11), 8.28 (1H, s, H-9), 8.72 (1H, s, H-6), 9.15 (1H, s, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.0 (C-1), 137.6 (C-3),117.3 (C-7), 77.4 (C-5), 120.7 (C-15a), 125.6 (C-6), 125.9 (C-11), 128.5 (C-9), 129.3 (C-10), 115.8 (C-4), 135.7 (C-16), 140.9 (C-14), 137.9 (C-12), 147.1 (C-13), 149.8 (C-15b), 152.8 (C-8). TOFF MS ES-: (m/z) [(M + Cl]- 495.9821 (100%) (Calculated for C18H13Cl2N5-(495.9593)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-4-flouroaniline (11d): As a light grey solid, yield 79%, mp-145-148, IR (cm-1) C-H 2900-3000, 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.44 (2H, d, J = 5.2 Hz, H-1), 6.15 (1H, t, J = 5.6 Hz, H-2), 6.71 (2H, dd, J1 = 9.1 Hz, J2 = 4.4 Hz, H-4), 6.96 (2H, t, J = 9.1 Hz, H-3), 7.79 (1H, dd, J1 = 9.0 Hz, J2 = 1.5 Hz, H-10), 7.82 (1H, d, J = 4.5 Hz, H-7), 8.01 (1H, d, J = 9.0, H-11), 8.29 (1H, d, J = 1.5 Hz, H-9), 8.73 (1H, s, H-6), 9.15 (1H, d, J = 4.5 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.0 (C-1), 113.7 (C-4), 115,8 (C-3), 117.3 (C-7), 120.7 (C-15a), 125.6 (C-6), 125.8 (C-11), 128.6 (C-9), 129.4 (C-10), 135.8 (C-16), 140.9 (C-14), 145.4 (C-12), 147.0 (C-13), 149.8 (C-15b), 152 (C-8), 154.3/155.8 (C-5). TOFF MS ES-: (m/z) [(M-H) - N2]- 324.0866 (100%) (Calculated for C18H12ClFN3-(324.0709)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-3-chloroaniline (11e): As a yellow solid, yield 69%, mp 169-172 ℃ , IR (cm-1) C-H 2900-3000, 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.48 (2H, d, J = 5.6 Hz, H-1), 6.53 (1H, t, J=Hz, H-2), 6.66 (H, t, J = 8.0 Hz, H-5), 6.74 (1H, s, H-3’), 6.74 (1H, dd, J1 = 3 Hz, J2 = 2.4 Hz H-4’), 7.10 (1H, dd, J1 = 9.2 Hz, J2 =1.9 Hz, H-3), 7.12 (1H, s, H-3), 7.80-7.79 (2H, m, H-7 and H-10), 8.01 (1H, d, J = 9.0 Hz, H-11), 8.27 (1H, d, J = 1.6 Hz, H-9), 8.72 (1H, s, H-6), 9.13 (1H, d, J = 4.5 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 38.6 (C-1), 112.1 (C-3), 111.5(C-3’), 117,3 (C-7), 130.8 (C-5), 120.7 (C-15a), 125.7 (C-6), 125.8 (C-11), 128.6 (C-9), 129.3 (C-10), 124.7 (C-4’), 135.8 (C-16), 134.1 (C-4), 140.9 (C-14), 150.2 (C-12), 147.0 (C-13), 149.8 (C-15b), 152.8 (C-8). TOFF MS ES-: (m/z) [(M-H) - N2]- 340.0580 (100%) (Calculated for C18H12Cl2N3-(340.0414)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-2-methoxyaniline (11f): As a brown liquid, yield 43%, IR (cm-1) C-H 2900-3000 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 3.79 (3H, s, H-3’’), 4.52 (2H, d, J = 6 Hz, H-1), 5.46 (1H, t, J = 6 Hz, H-2), 6.59 (1H, td, J1 = 7.7 Hz, J2 = 1.4 Hz, H-5), 6.72 (1H, dd, J1 = 7.7 Hz, J2 = 1.4, H-3’), 6.78 (1H, d, J = 8.0 Hz, H-4), 6.83 (1H, td, J1 = 7.7 Hz, J2 = 0.6 Hz, H-4’), 7.76 (1H, dd, J1 = 9.1 Hz, J2 = 2.1 Hz, H-10), 7.81 (1H, d, J = 4.6 Hz, H-7), 8.01 (1H, d, J = 9.1 Hz, H-11), 8.26 (1H, d, J = 2.0 Hz, H-9), 8.69 (1H, s, H-6), 9.12 (1H, d, J = 4.6 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.0 (C-1), 110.2 (C-3’), 138.0 (C-3), 117,3 (C-7), 116.7 (C-5), 120.7 (C-15a), 125.6 (C-6), 125.9 (C-11), 128.5 (C-9), 129.3 (C-10), 110.3 (C-4), 135.7 (C-16), 121.4 (C-4’), 140.9 (C-14), 137.9 (C-12), 147.1 (C-13), 149.8 (C-15b), 152.8 (C-8), 55.7 (C-3’’). TOF MSMS ES+: (m/z) 388.1096 (M+Na)+ [Calculated for C19H16ClN5NaO (388.0941)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-2-triflouromethylaniline (11g): As a yellow liquid, yield 48%, IR (cm-1) C-H 2900-3000 1H-NMR(DMSO-d6, 600 MHz, ppm) δH 4.65 (2H, d, J = 5.7 Hz, H-1), 6.11 (1H, s, H-2), 6.73 (1H, t, J = 7.5 Hz, H-5), 7.01 (1H, d, J = 8.4 Hz, H-3’), 7.43 (1H, m, H-4,4’), 7.76 (1H, dd, J1 = 9.0 Hz, J2 = 2.0 Hz, H-10), 7.80 (1H, d, J = 4.6 Hz, H-7), 7.96 (1H, d, J = 9.0 Hz, H-11), 8.25 (1H, d, J = 2.0, H-9), 8.65 (1H, s, H-6), 9.11 (1H, d, J = 4.6 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.0 (C-1), 145.4 (C-3), 112.9 (C-3’), 117.4 (C-7), 116.2 (C-5), 120.7 (C-15a), 126.1 (C-6), 125.8 (C-11), 128.5 (C-9), 129.3 (C-10), 126.7 (C-4’), 135.8 (C-16), 134.0 (C-4), 140.9 (C-14), 146.5 (C-12), 146.5 (C-13), 149.8 (C-15b), 152.8 (C-8),126 (C-3’’).
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-3-flouroaniline (11h): As a crem white solid, yield 85%, mp 145-148 ℃ , IR (cm-1) C-H 2900 1H-NMR (DMSO-d6, 600 MHz, ppm) δH 4.47 (2H, d, J = 5.7 Hz, H-1), 5.40 (1H, s, H-2), 6.35 (1H, td, J1 = 8.6, J2= 2 Hz, H-4), 6.49 – 6.55 (3H, m, H-3, H-3’ and H5), 7.76 (1H, dd, J1 = 9.0 Hz, J2 = 1.9 Hz, H-10), 7.80 (1H, d, J = 4.7 Hz, H-7), 8.00 (1H, d, J = 9.2 Hz, H-11), 8.28 (1H, s, Hz, H-9), 8.72 1(H, s, H-6), 9.13 (1H, d, J = 4.6 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 38.7 (C-1), 99.2 (C-3), 109.2 (C-3’), 117.3 (C-7), 130.7 (C-5), 143.5 (C-4’) 120.7 (C-15a), 125.6 (C-6), 125.9 (C-11), 128.5 (C-9), 129.4 (C-10), 135.8 (C-16), 165.1(C-4), 140.9 (C-14), 153.5 (C-12), 146.6 (C-13), 149.8 (C-15b), 152.8 (C-8). TOFF MS ES-: (m/z) [(M-H) - N2]- 324.0868 (100%) (Calculated for C18H12ClFN3-(324.0709)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-3-nitroaniline (11i): As a orange solid, yield 79%, mp 192-197 ℃ , IR (cm-1) C-H 2900-3000. 1H-NMR(DMSO-d6, 600 MHz, ppm) δH 4.58 (2H, d, J = 5.7 Hz, H-1), 7.00 (H, s, H-2), 7.15 (1H, d, J = 7.74 Hz, H-3’), 7.37 (2H, m, H-4’ and H-5), 7.52 (1H, d, J = 7.7 Hz, H-3), 7.77 (1H, t, J = 2.0 Hz, H-10), 7.78 (1H, dd, J1 = 8.7 Hz, J2 = 2, H-7), 7.81 (H, dd, J1 = 9.0 Hz, J2 = 1.5 Hz, H-11), 8.29 (1H, d, J = 2 Hz, H-9), 8.77 (1H, s, H-6), 9.14 (1H, d, J = 4.5 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 39.1 (C-1), 130 (C-4’), 106 (C-3’), 117.4 (C-7), 119.1 (C-3) 120.8 (C-15a), 125.8 (C-6), 125.8 (C-11), 128.6 (C-9), 129.4 (C-10), 135.8 (C-16), 140.9 (C-14), 145.4 (C-12), 146.2 (C-13), 149.81 (C-4), 149.8 (C-15b), 152 (C-8), 111.0 (C-5). TOF MSMS ES+: (m/z) 381.2533 (M+1)- [Calculated for C18H14ClN6O2 (381.7920)].
[1-(7-Chloro-4-quinolinyl)-1H-1,2,3-triazole-4-methyl]-4-methoxyaniline (11j): As a brown solid, yield 86%, mp-xx, IR (cm-1) C-H 2900-3000. 1H-NMR(DMSO-d6, 600 MHz, ppm) δH 3.64 (3H, s, H-5’), 4.42 (2H, d, J = 5.8 Hz, H-1), 5.76 (1H, t, J = 5.8 Hz, H-2), 6.68 (2H, d, J = 8.8 Hz, H-4), 6.74 (2H, d, J = 8.8 Hz, H-3), 7.75 (1H, dd, J1 = 9.0 Hz, J2 = 1.8 Hz, H-10), 7.79 (1H, d, J = 4.6 Hz, H-7), 8.01 (1H, d, J = 9.0 Hz, H-11), 8.25 (1H, d, J = 1.7 Hz, H-9), 8.68 (1H, s, H-6), 9.11 (1H, d, J = 4.6 Hz, H-8). 13C-NMR (DMSO-d6, 150 MHz, ppm) δC 40.4 (C-1), 115.07 (C-3), 117.2 (C-7), 151.6 (C-5), 55.7 (C-5’), 120.7 (C-15a), 125.6 (C-6), 125.9 (C-11), 128.5 (C-9), 129.3 (C-10), 135.7 (C-16), 114.1 (C-4), 140.9 (C-14), 142.9 (C-12), 147.1 (C-13), 149.8 (C-15b), 152.8 (C-8). TOFF MS ES-: (m/z) [(M-H) - N2]- 336.1097 (100%) [Calculated for C19H15ClN3O- (336.0909)].

3.2. Biology

3.2.1. Antimycobacterial Evaluation

In vitro antimycobacterial evaluation assay was performed against the H37Rv strain using the previously reported procedure [22]. Cultured H37Rv (ATCC 27294) in Middlebrook 7H9 (Difco) broth supplemented with 0.1 % glycerol (Merck) and 10 % oleic acid-albumin-dextrose-catalase (OADC) (Becton-Dickenson) were aerobically grown at 37 °C until an optical density (OD)600nm of 1 was attained. This was equivalent to approximately 3 x 108 bacilli/mL.
The antimicrobial activity of the various compounds was tested in triplicates using micro broth dilution assays in 96 well plates. These plates were sealed and incubated at 37 °C for 7 days and microbial growth was measured by observing the resazurin colour change from blue to pink. The minimum inhibitory concentration (MIC) was interpreted as the lowest concentration inhibiting a colour change from blue to pink.

3.2.2. MTT Cytotoxicity Evaluation

In vitro cytotoxicity evaluation assay was performed on the TZM-bl cell line, a HeLa cell line clone, as previously reported [22]. The cell were seeded at a density of 25000 (DEAE dextran 44 µl/10ml) cells + 150µl DMEM/well in a 96-well microtiter plate, in duplicates and incubated overnight for attachment (37℃, 5% CO2). Treatments (2.5mg/ml) were prepared and following incubation, the supernatant (treatment medium) was removed, and 120 µl of MTT solution comprising 100µl fresh CCM and 20µl of MTT (5mg/ml MTT salt in 0.1M PBS) was added to each well. The plate was then incubated for 4 hours (37℃, 5% CO2). The optical density of each sample was measured at 450 using a microplate reader (Perkin Elmer). The maximum inhibitory concentration resulting in 50% cytotoxicity concentration (CC50) was obtained using GraphPad Prism version 5.01 by plotting a dose-response curve (concentration versus the percentage cell viability of the samples). (see cytotoxicity dose-response curved in the supplementary information).

3.2.3. Luciferase-Based Antiviral Assay Evaluating Human Immunodeficiency Virus

Maintenance of Cell Lines

In sterile 75 cm2 culture flasks, the TZM-bl cell lines (NIH AIDS Research and Reference Reagents Programme) were cultured as a monolayer using Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; heat-inactivated and gamma irradiated) (LTC Biosciences, Gainesville, FL, USA), 25 mM of HEPES (Thermo Fisher Scientific, Waltham, MA, USA), and 50 μL/mL of gentamicin (Thermo Fisher Scientific, Waltham, MA, USA). A HeLa cell line clone, the TZM-bl cell line is altered to produce CD4 and CCR5, enabling HIV-1 infection and firefly luciferase regulated by the HIV-1 long-terminal repeat (LTR) [53].

Antiviral Assay

The HIV-1 inhibition of synthesised drugs was evaluated using a Luciferace-based antiviral assay [54]. Initially, 96-well cell culture plates were filled with 150 uL, 100 uL, and 140 uL of DMEM; test compound, viral control, and cell control were added, respectively. Briefly, 96-cell culture well plates (Corning Costar, New York, NY, USA) were filled with 11 uL of AZT drug (positive control) and test compounds. The plates were then diluted three times in 140 uL of DMEM supplemented with 10% FBS, 25% HEPES buffer, and 1% penicillin-streptomycin. 10,000 TZM-bl cell lines were infected with 50 uL NL4.3 virus (subtype B) in 96 well culture plates. Experimental controls included infected (virus control) and uninfected (cell control) TZM-bl cell line, which was incubated for an hour. After adding 10,000 cells to each 96-well plate, the cells were grown for 48 hours at 37 °C, 5% CO2, 95% humidity, and 37.5 ug/mL of DEAE-dextran. 150 ul of medium was taken out and replaced with 100 uL of the Bright-Glo TM luciferase reagent without light exposure following a 48-hour incubation period. After aspirating the supernatant, 150 uL of the mixture containing the Bright-Glo TM luciferase reagent was put into a Corning Costar 96-well black plate. It was measured right away at 540 nm in the Victor Nivo microplate reader (PerkinElmer, Waltham, USA). Then, the percentage of viral inhibition was calculated as follows:
% HIV inhibition = (average sample–average control)/(1 − (average viral control–average control) × 100
The results of the absorbance-based quantification of the viral cell were through the inhibitory concentration at 50% was obtained by plotting the dose-response curve (log concentration versus % HIV inhibition) (see HIV assay dose-response curved in the supplementary information).

3.3. In Silico Studies

3.3.1. Molecular Docking

The compounds and proteins were prepared using the ligand preparation (LigPrep) and protein preparation wizard modules [55] (on Maestro software in Schrödinger Suite [45]). The compounds were docked at the active sites of the proteins.

3.3.2. DFT Studies

The structure of 11h was optimised at the DFT/B3LYP/6-311++G(d,p) level of theory in the gas phase. Frequency calculations of the optimised structure were performed to ensure that the geometry conforms to minima. The ionisation potential and electron affinity were calculated from the frontier molecular orbital energies (EHOMO) and (ELUMO), respectively [56]. Other reactivity indices such as the energy gap (Eg), chemical hardness and softness (η and S, respectively), electronegativity (χ) and electrophilicity (ω) were all calculated [57]; see equations 1-8. The distribution of the molecular orbitals over the molecular surface was visualised via the HOMO and LUMO maps [51]. An electrostatic potential (ESP) map was used to visualise the selective reactive sites of interaction of 11h with an electron donating or withdrawing neighbour [58].
I = − E H O M O
A = − E L U M O
E g = E L U M O − E H O M O
η = I − A 2
S = 1 η
χ = I + A 2
ω = ( I + A ) 2 8 η = χ 2 2 η

4. Conclusions

Applying molecular hybridisation, new quinoline-1,2,3-triazole-anilines were successfully synthesised in moderate to excellent yields. Their structures were confirmed using spectroscopic and spectrometric techniques. The synthesised compounds demonstrated moderate to negligible activity against Mtb in vitro. However, notable anti-HIV activity was observed in compounds 11g, 11h and 11i, with their IC50 being 0.3883 µM, 0.0103 µM and 0.167 µM, respectively, with 11h exhibiting the best activity against both Mtb and HIV. Furthermore, 11h showed 9-fold superior activity than the reference drug, AZT (0.0909 µM).
Additionally, the presence of fluoride in certain compounds appears to have improved antiviral activity. Cytotoxicity assessments generally revealed low toxicity except for a few compounds. Selective indices (SI) of 11g and 11h are 11367 and 2472.87, respectively, suggesting that these compounds would pose less cytotoxic effects in vivo. Molecular docking studies revealed that 11h interacted with some of the essential amino acid residues in the active site of the HIV-1 co-receptor entry enzyme. The DFT studies on 11h revealed reactivity and reactive sites in the compound, while the predicted ADMET parameters for most compounds indicated drug-like molecules. Thus, 11h is a potential hit for further optimisation studies against HIV-1.

Supplementary Materials

The following are available online [Cell viability plot, 1H and 13C NMR and 2D-NMR spectra of the synthesised target compounds, IR spectra, MS data, cytotoxicity assay dose-response curves and HIV assay dose-response curves).

Author Contributions

Methodology, formal analysis, writing-original draft, S.S.M.; Methodology, formal analysis, writing-reviewing & editing, D.N.; Methodology, formal analysis, validation, writing-reviewing & editing, O.E.O.; Methodology, formal analysis, writing-reviewing & editing, S.S.; Conceptualization, supervision, formal analysis, funding acquisition, writing-reviewing & editing, N.P.M.; Conceptualization, supervision, project administration, funding acquisition, formal analysis, writing-reviewing & editing, M.T. All authors have read and agreed to the published version of the manuscript.

Funding

The South African National Research Foundation (NRF)’s Competitive Support for unrated research grants [CSUR: 116285(M.T.)], South African Medical Research Council Self-Initiated Research (N.P.M.), and UKZN are gratefully acknowledged for financial and other valuable support. Tertiary Education Trust Fund (TETFUND), from the Government of the Republic of Nigeria, for the Postdoctoral Fellowship Award (TETF/ES/UNIV/ONDO STATE/TSAS/2021) (O.E.O.). The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the funders.

Institutional Review Board Statement

Not applicable

Informed Consent Statement

Not applicable
Data availability: Original experimental data not provided in the supplementary information are available from the authors on request.

Acknowledgments

All computational calculations were carried out using resources at the Centre for High-Performance Computing (CHPC), Cape Town, South Africa.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Global Tuberculosis Report 2024. World Health Organisation: Geneva, 2024. https://iris.who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1 (Accessed on 17 January 2025).
  2. Quimque, M.T.G.; Go, A.D.; Lim, J.A.K.; Vidar, W.S.; Macabeo, A.P.G. Mycobacterium tuberculosis Inhibitors Based on arylated quinoline carboxylic acid backbones with anti-Mtb gyrase activity. Int. J. Mol. Sci. 2023, 24 (14), 11632. https://doi.org/10.3390/ijms241411632. [CrossRef]
  3. Martinez, R.M. Bacillus subtilis, in Brenner's Encyclopedia of Genetics (2nd Ed), S. Maloy and K. Hughes, Editors. 2013, Academic Press: San Diego, 246-248.
  4. Smith, T., Wolff, K.A.; Nguyen, L. Molecular biology of drug resistance in Mycobacterium tuberculosis. Curr. Top. Microbiol. Immunol. 2013. 374: p. 53-80. https://doi.org/10.1007/82_2012_279. [CrossRef]
  5. Sawyer, E.B.; Grabowska, A.D.; Cortes, T. Translational regulation in mycobacteria and its implications for pathogenicity. Nucleic Acids Res. 2018, 46(14): 6950-6961. https://doi.org/10.1093/nar/gky574. [CrossRef]
  6. Bhat, Z.S.; Rather, M.A.; Maqbool, M.; Ahmad, Z. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon. Biomed. Pharmacother. 2018, 103, 1733-1747. https://doi.org/10.1016/j.biopha.2018.04.176. [CrossRef]
  7. Amusengeri, A.; Khan, A.; Tastan Bishop, O. The structural basis of Mycobacterium tuberculosis RpoB drug-Resistant clinical mutations on rifampicin drug binding. Molecules, 2022, 27(3), 885. https://doi.org/10.3390/molecules27030885. [CrossRef]
  8. Goldberg, D.E.; Siliciano, R.F.; Jacobs, W.R. Outwitting evolution: Fighting drug-resistant TB, malaria, and HIV. Cell, 2012, 148(6), 1271-1283. https://doi.org/10.1016/j.cell.2012.02.021. [CrossRef]
  9. Aguilar Diaz, J.M.; Abulfathu, A.A.; te Brake, L.H.M.; van Ingen, J.; Kuipers, S.; Magis-Escurra, C.; Raiijmaker, J.; Svensson, E.M., Boeree, M.J. New and repurposed drugs for the treatment of active tuberculosis: An Update for clinicians. Respiration, 2023, 102(2), 83-100. https://doi.org/10.1159/000528274. [CrossRef]
  10. Rendon, A.; Tiberi, S.; Scardigli, A.; D'Ambrosio, L.; Centis, R.; Caminero, J.A.; Migloori, G.B. Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. J. Thorac. Dis. 2016, 8(10), 2666-2671. https://doi.org/10.21037/jtd.2016.10.14. [CrossRef]
  11. Karim, Q.A.; Karim, S.S.A. The evolving HIV epidemic in South Africa. Int. J. Epidemol. 2002, 31(1), 37-40. https://doi.org/10.1093/ije/31.1.37. [CrossRef]
  12. The urgency of now: AIDS at a crossroads, Joint United Nations Programme on HIV/AIDS: Geneva, 2024. https://www.unaids.org/sites/default/files/media_asset/2024-unaids-global-aids-update_en.pdf (accessed 17 March 2025).
  13. Maeda, K.; Das, D.; Kobayakawa, T.; Tamamura, H.; Takeuchi, H. Discovery and development of anti-HIV therapeutic agents: Progress towards improved HIV medication. Curr. Top. Med. Chem. 2019, 19(18), 1621-1649. https://doi.org/10.2174/1568026619666190712204603. [CrossRef]
  14. Phanuphak, N.; Gulick, R.M. HIV treatment and prevention 2019: Current standards of care. Curr. Opin. HIV AIDS, 2020, 15(1), 4-12. https://doi.org/10.1097/COH.0000000000000588. [CrossRef]
  15. Arts, E.J.; Hazuda, D.J. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2012, 2(4): a007161. https://doi.org/10.1101/cshperpspect.a007161. [CrossRef]
  16. Holec, A.D.; Mandal, S.; Prathipati, P.K.; Destache, C.J. Nucleotide reverse transcriptase inhibitors: A thorough review, present status and tuture perspective as HIV therapeutics. Curr. HIV Res. 2017, 15(6), 411-421. https://doi.org/10.2174/1570162X15666171120110145. [CrossRef]
  17. Koren, D.E.. 225 Classes of antiretrovirals, in Fundamentals of HIV Medicine. 2020, Oxford University Press, New York. 225-238.
  18. Di, L. and E.H. Kerns. Drug-like properties: Concepts, structure design and methods from ADME to toxicity optimization. 2012, Academic Press, Califonia.
  19. Sluis-Cremer, N.; Tachedjian, G. Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008, 134(1-2), 147-156. https://doi.org/10.1016/j.virusres.2008.01.002. [CrossRef]
  20. Ramprasad, J.; Sthalam, V.K.; Thampunuri, R.L.M.; Bhukya, S.; Ummanni, R.; Balasubramanian, S.; Pabbaraja, S. Synthesis and evaluation of a novel quinoline-triazole analogs for antitubercular properties via molecular hybridization approach. Bioorg. Med. Chem. Lett. 2019, 29(20), 126671. https://doi.org/10.1016/j.bmcl.2019.126671. [CrossRef]
  21. Thomas, K.D.; Adhikari, A.V.; Chowdhury, I.H.; Sumesh, E.; Pal, N.K. New quinolin-4-yl-1,2,3-triazoles carrying amides, sulphonamides and amidopiperazines as potential antitubercular agents. Eur. J. Med. Chem. 2011, 46 (6), 2503-2512. https://doi.org/10.1016/j.ejmech.2011.03.039. [CrossRef]
  22. Nyoni, N.T.P.; Ncube, N.B.; Kubheka, M.X.; Mkhwanazi, N.P.; Senzani, S.; Tukulula, M. Synthesis, characterization, in vitro antimycobacterial and cytotoxicity evaluation, DFT calculations, molecular docking and ADME studies of new isomeric benzimidazole-1,2,3-triazole-quinoline hybrid mixtures. Bioorg. Chem. 2023, 141: 106904. https://doi.org/10.1016/j.bioorg.2023.106904. [CrossRef]
  23. Reddyrajula, R.; Dalimba, U. Quinoline-1,2,3-triazole hybrids: Design and synthesis through Click Reaction, evaluation of antitubercular activity, molecular docking and in silico ADME studies. ChemistrySelect, 2019, 4(9), 2685-2693. https://doi.org/10.1002/slct.201803946. [CrossRef]
  24. Ganesan, M.S.; Raja, K.K.; Murugesan, S.; Karankumar, B.; Faheem, F.; Thirunavukkarasu, S.; Shetye, G.; Ma, R.; Franzablau, S.G.; Wan, B.; Rajagopal, J. Quinoline-proline, triazole hybrids: Design, synthesis, antituberculosis, molecular docking, and ADMET studies. J. Heterocycl. Chem. 2021, 58(4), 952-968. https://doi.org/10.1002/jhet.4229. [CrossRef]
  25. Yadav, J.; Kaushik, C.P. Quinoline-1,2,3-triazole hybrids: Design, synthesis, antimalarial and antimicrobial evaluation. J. Mol. Struct. 2024, 1316: 138882. https://doi.org/10.1016/j.molstruc.2024.1388882. [CrossRef]
  26. Thakare, P.P.; Shinde, A.D.; Chavan, A.P.; Nyayanit, N.V.; Bobade, V.D.; Mhaske, P.C. Synthesis and biological evaluation of new 1,2,3-triazolyl-pyrazolyl-quinoline derivatives as potential antimicrobial agents. ChemistrySelect, 2020, 5(15), 4722-4727. https://doi.org/10.1002/slct.201904455. [CrossRef]
  27. Jamshidi, H.; Naimi-Jamal, M.R.; Safavi, M.; Sanati, K.R.; Azerang, P.; Tahhighi, A. Synthesis and biological activity profile of novel triazole/quinoline hybrids. Chem. Biol. Drug Des. 2022, 100(6), 935-946. https://doi.org/10.1111/cbdd.14031. [CrossRef]
  28. Bhoye, M.R.; Shinde, A.; Shaik, A.L.N.; Shisode, V.; Chavan, A.; Maliwal, D.; Pisssurlenkar, R.R.S. New thiazolyl-isoxazole derivatives as potential anti-infective agents: design, synthesis, in vitro and in silico antimicrobial efficacy. J. Biomol. Struct. Dynamic. 2024, 23, 1-15. https://doi.org/10.1080/07391102.2024.2306497. [CrossRef]
  29. Costa, C.C.P.; Boechat, N.; Bastos, M.M.; da Silva, F-de.C.; Marttorelli, A.; Souza, T.M.L; Baptista, M.S.; Hoelz, L.V.B.; Caffarena, E.R. New efavirenz derivatives and 1,2,3-triazolyl-phosphonates as inhibitors of reverse transcriptase of HIV-1. Curr. Top. Med. Chem. 2018, 18(17), 1494-1505. https://doi.org/10.2174/1568026618666181029150118. [CrossRef]
  30. Feng, L.S.; Zheng, M-J.; Zhao, F.; Liu, D. 1,2,3-Triazole hybrids with anti-HIV-1 activity. Arch. Pharm. 2021, 354(1), e2000163. https://doi.org/10.1002/ardp.202000163. [CrossRef]
  31. Tian, Y., Liu, Z.; Huang, B.; Kang, D.; Zhang, H.; De Clercq, E.; Daelemans, D.; Pannecouque, C.; Leé, K-H.; Chen, C-H.; Zhan, P.; Liu, Z. Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. Eur. J. Med. Chem. 2018, 151, 339-350. https://doi.org/10.1016/j.ejmech.2018.03.059. [CrossRef]
  32. Zhou, Z.; Liu, T.; Wu, G.; Kang, D.; Fu, Z.; Wang, Z.; De Clercq, E.; Pannecouque, C.; Zhan, P. Liu, X. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus. Org. Biomol. Chem. 2019, 17, 3202-3217. https://doi.org/10.1039/C9OB00032A. [CrossRef]
  33. Ahmad, A.; Akthar, J.; Ahmad, M.; Khan, M.I.; Wasim, R.; Islam, A.; Singh. A. Bedaquiline: An Insight Into its clinical use in multidrug-resistant pulmonary tuberculosis. Drug. Res. 2024, 74(6), 269-279. https://doi.org/10.1055/a-2331-7061. [CrossRef]
  34. Sutherland, H.S.; Tong, A.S.T.; Choi, P.J.; Blaser, A.; Conobe, D.; Franzblau, S.G.; Lotlikar, M.U.; Cooper, C.B.; Upton, A.M.; Denny, W.A.; Palmer, B.D. 3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel. Bioorg. Med. Chem. 2019, 27(7), 1292-1307. https://doi.org/10.1016/j.bmc.2019.02.026. [CrossRef]
  35. Emu, B.; Fessel, J.; Schrader, S.; Kumar, P.; Richmond, G.; Win, S.; Weinheimer, S. Marsolais, C.; Lewis, S. Phase 3 study of ibalizumab for multidrug-resistant HIV-1. N. Engl. J. Med. 2018, 379(7), 645-654. https://doi.org/10.1056/NEJMoa1711460. [CrossRef]
  36. Xu, G.G.; Guo, J.; Wu, Y. Chemokine Receptor CCR5 antagonist Maraviroc: Medicinal chemistry and clinical applications. Curr. Top. Med. Chem. 2014, 14(13), 1504-1514. https://doi.org/10.2174/1568026614666140827143745. [CrossRef]
  37. Price, D.A.; Armour, D.; de Groot, M.; Leishman, D.; Napier, C.; Perros, M.; Stammen, B.L.; Wood, A. Overcoming hERG affinity in the discovery of maraviroc; a CCR5 antagonist for the treatment of HIV. Bioorg. Med. Chem. Lett. 2006, 16(17), 4633-4637. https://doi.org/10.1016/j.bmcl.2006.06.012. [CrossRef]
  38. Manosuthi, W.; Wiboonchutikul, S; Sungkanuparph, S. Integrated therapy for HIV and tuberculosis. AIDS Res. Ther. 2016, 13:22. https://doi.org/10.1186/s12981-016-0106-y. [CrossRef]
  39. Khan, S.A.; Akthar, M.J.; Gogoi, U.; Meenakshi, D.U.; Das, A. An overview of 1,2,3-triazole-containing hybrids and their potential anticholinesterase activities. Pharmaceuticals, 2023, 16(2): 179. https://doi.org/10.3390/ph16020179. [CrossRef]
  40. Eswaran, S.; Adhikari, A.V.; Shetty, N.S. Synthesis and antimicrobial activities of novel quinoline derivatives carrying 1,2,4-triazole moiety. Eur. J. Med. Chem. 2009, 44(11), 4637-4647. https://doi.org/10.1016/j.ejmech.2009.06.031. [CrossRef]
  41. Casano, G.; Dumétre, A.; Panneouque, C.; Hutter, S.; Azas, N.; Robin, M. Anti-HIV and antiplasmodial activity of original flavonoid derivatives. Bioorg. Med. Chem. 2010, 18 (16), 6012-6023. https://doi.org/10.1016/j.bmc.2010.06.067. [CrossRef]
  42. Indrayanto, G., Putra, G.S.; Suhud, F. Chapter Six - Validation of in-vitro bioassay methods: Application in herbal drug research, in Profiles of Drug Substances, Excipients and Related Methodology, A.A. Al-Majed, Editor. Profiles Drug Subst. Excip. Relat. Methodol. 2021, 46, 273-307. https://doi.org/10.1016/bs.podrm.2020.07.005. [CrossRef]
  43. Kumar, S.; Mehra, R.; Sharma, S., Bokolia, N.P.; Raina, D.; Nargotra, A.; Singh, P.P.; Khan, I.A. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis. Tuberculosis, 2018, 108, 56-63. https://doi.org/10.1016/j.tube.2017.10.008. [CrossRef]
  44. El-Zohairy, M.A.; Zlotos, D.P.; Berger, M.R.; Adwan, H.H.; Mandour, Y.M. Discovery of Novel CCR5 Ligands as anticolorectal cancer agents by sequential virtual screening. ACS Omega, 2021, 6 (16), 10921-10935. https://doi.org/10.1021/acsomega.1c00681. [CrossRef]
  45. Vadivelu, A.; Gopal, V.; Reddy, C.U.M. Molecular docking studies of 1, 3, 4-thiadiazoles as novel peptide deformylase inhibitors as potential antibacterial agents. Int. J. Pharm. Sci. Rev. Res. 2015, 31(1) 58-62. https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=327843d2a59588c3263726dc53a4b9d2f04c519f.
  46. Shah, P.; Naik. D.; Jariwala, N.; Bhadane, D.; Kumar, S.; Kulkarni, S.; Bhutani, K.K.; Singh, I.P. Synthesis of C-2 and C-3 substituted quinolines and their evaluation as anti-HIV-1 agents. Bioorg. Chem. 2018, 80, 591-601. https://doi.org/10.1016/j.bioorg.2018.07.016. [CrossRef]
  47. Ibrahim, T.S.; Bokhtia, R.; Al-Mahmoudy, A.M.M.; Taher, E.S.; AlAwadh, M.A.; Elagawany, M.; Abdel-Aal, E.H.; Panda, S.; Gouda, A.M.; Asfour, H.Z.; Alhakamy, N.A.; Youssif, B.G.M. Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors. Bioorg. Chem. 2020, 99,103782. https://doi.org/10.1016/j.bioorg.2020.103782. [CrossRef]
  48. Oyeneyin, O.E.; Ojo, N.D.; Ipinlogu, N.; James, A.C.; Agbaffa, E.B. Investigation of corrosion inhibition potentials of some aminopyridine Schiff bases using density functional theory and Monte Carlo simulation. Chem. Afr. 2022, 5, 319-322. https://doi.org/10.1007/s42250-021-00304-1. [CrossRef]
  49. Zhan, C.-G.; Nichols, J.A.; Dixon, D.A. Ionization potential, electron affinity, electronegativity, dardness, and electron excitation energy:  Molecular properties from density functional theory orbital energies. J. Phys. Chem. A, 2003, 107(20). 4184-4195. https://doi.org/10.1021/jp0225774. [CrossRef]
  50. Kadi, I.; Güldeniz, S.; Bouled, H.; Zebbiche, Z.; Suat, T.; Fatümetüzzehra, K.; Gönül, Z.; Küçükbay, H.; Boumoud, T. Synthesis, cytotoxicity, antioxidant activity, DFT calculations, and docking studies of new pyridine-malonate derivatives as potential anticancer agents. Polycycl. Aromat. Compd. 2022, 44(10), 6615-6629. https://doi.org/10.1080/10406638.2023.2281468. [CrossRef]
  51. Hussain, Z.; Ibrahim, M.A.; Hassanin, N.M.; Badran, A-S. Synthetic approaches for novel annulated pyrido[2,3-d]pyrimidines: Design, structural sharacterization, Fukui functions, DFT calculations, molecular docking and anticancer efficiency. J. Mol. Struct. 2024, 1318(1), 139335. https://doi.org/10.1016/j.molstruc.2024.139335. [CrossRef]
  52. Roskoski Jr, R. Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacol. Res. 2024, 200: 107059. https://doi.org/10.1016/j.phrs.2024.107059. [CrossRef]
  53. Wei, X.; Decker, M.J.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilny, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 2002, 46(6), 1896-1905. https://doi.org/10.1128/AAC.46.6.1896-1905.2002. [CrossRef]
  54. Naidu, D.; Oduro-Kwateng, E.; Solima, M.E.S.; Ndlovu, S.I.; Mkhwanazi, N.P. Alternaria alternata (Fr) Keissl crude extract inhibits HIV subtypes and integrase drug-resistant strains at different stages of HIV replication. Pharmaceuticals, 2025, 18(2), 189. https://doi.org/10.3390/ph18020189. [CrossRef]
  55. Sastry, M.G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 2013, 27(3), 221-234. https://doi.org/10.1007/s10822-013-9644-8. [CrossRef]
  56. Mohammadpourasl, S.; de Biani, F.F.; Coppola, C.C.; Parisi, M.L.; Zani, L.; Dessi, A.; Calamante, M.; Reginato, G.; Basosi, R.; Sinicropi, A. Ground-State redox potentials calculations of D-π-A and D-A-π-A organic dyes for DSSC and visible-light-driven hydrogen production. Energies, 2020, 13(8) 2032. https://doi.org/10.3390/en13082032. [CrossRef]
  57. Aslam, R., Serdaoglu, G.; Zehra, S.; Verma, K.D.; Aslam, J.; Guo, L.; Verma, C.; Ebenzo, E.E.; Quraishi, M.A. Corrosion inhibition of steel using different families of organic compounds: Past and present progress. J. Mol. Liq. 2022, 348, 118373. https://doi.org/10.1016/j.molliq.2021.118373. [CrossRef]
  58. Ibrahim, M.A., Roushdy, N.; Atta, A.A.; Badran. A-S.; Farag, A.A.M. Comprehensive study on pyrano[3,2-c]quinoline-based indole: Synthesis, characterization, and potential for optoelectronic and photovoltaic applications. J. Mol. Struct. 2024, 1312, 138660. https://doi.org/10.1016/j.molstruc.2024.138660. [CrossRef]
Preprints 155523 g001
Figure 1. Quinoline and triazole-containing compounds that show antitubercular and antiviral activity.
Figure 1. Quinoline and triazole-containing compounds that show antitubercular and antiviral activity.
Preprints 155523 g001
Preprints 155523 g002
Figure 2. Rationale for the target compounds.
Figure 2. Rationale for the target compounds.
Preprints 155523 g002
Preprints 155523 sch001
Scheme 1. Synthesis of the target compounds 11a-j. Reagents and conditions: (i) NaN3, DMF, 85 °C, 24 hrs; (ii) K2CO3, DCM, rt, 24 hrs; (iii) sodium ascorbate, CuSO4, DCM, 24 hrs.
Scheme 1. Synthesis of the target compounds 11a-j. Reagents and conditions: (i) NaN3, DMF, 85 °C, 24 hrs; (ii) K2CO3, DCM, rt, 24 hrs; (iii) sodium ascorbate, CuSO4, DCM, 24 hrs.
Preprints 155523 sch001
Preprints 155523 g003
Figure 3. HMBC spectrum in DMSO-d6 and illustration of vital HMBC correlation in compound 11a.
Figure 3. HMBC spectrum in DMSO-d6 and illustration of vital HMBC correlation in compound 11a.
Preprints 155523 g003
Preprints 155523 g004
Figure 4. Docking interaction for the most promising compounds 11a and 11h (Top - Mtb docking interactions; bottom – antiviral docking interactions).
Figure 4. Docking interaction for the most promising compounds 11a and 11h (Top - Mtb docking interactions; bottom – antiviral docking interactions).
Preprints 155523 g004
Preprints 155523 g005
Figure 5. (a) HOMO and (b) LUMO maps of 11h.
Figure 5. (a) HOMO and (b) LUMO maps of 11h.
Preprints 155523 g005
Preprints 155523 g006
Figure 6. Electrostatic potential map of 11h.
Figure 6. Electrostatic potential map of 11h.
Preprints 155523 g006
Table 1. Yields, melting points and masses of the target compounds.
Table 1. Yields, melting points and masses of the target compounds.
Preprints 155523 i001
Compound Phenyl Appearance % Yield m.p. (°C) MS data
11a Preprints 155523 i002 cream white solid 88 150-152 306.0968 [(M-H)-N2]-
11b Preprints 155523 i003 light brown solid 87 188-190 449.9707 [(M+HCl]-
11c Preprints 155523 i004 brown solid 92 198-199 495.9821 [(M-H)+Cl]-
11d Preprints 155523 i005 light grey solid 79 145-147 324.0866 [(M-H)-N2]-
11e Preprints 155523 i006 Yellow solid 69 169-171 340.0580 [(M-H)-N2)]-
11f Preprints 155523 i007 dark brown liquid 43 - 388.1096 (M+Na)+
11g Preprints 155523 i008 Yellow liquid 48 - -
11h Preprints 155523 i009 cream white solid 85 145-147 324.0868 [(M-H)-N2]-
11i Preprints 155523 i010 Orange solid 79 192-194 381.2533 (M+1)-
11j Preprints 155523 i011 Brown solid 86 169-172 336.1097 [(M-H)-N2]-
Table 2. Anti-Mtb, -HIV and cytotoxicity evaluation of quinoline 1,2,3-triazole-anilines.
Table 2. Anti-Mtb, -HIV and cytotoxicity evaluation of quinoline 1,2,3-triazole-anilines.
Compound Anti-Mtb (µM) Anti-HIV (µM) Cytotoxicity CC50 (µM) SIa
H37Rv MIC90 HIV-1 Subtype B IC50 TZM-bl cell line (CC50/IC50)
11a 186.52 3.013 177.1 58.75
11b 1210.65 124.4 0.248 1.994 x 10-3
11c 1084.6 23.20 156.9 6.76
11d 176.52 DNC* 1320.0 -
11e 168.81 713.7 834.6 1.17
11f 171.19 22.75 3.599 0.158
11g 155.05 0.3883 4414 11367.49
11h 88.72 0.01032 25.52 2472.87
11i nd* 0.167 0.00901 0.05
11j 1369.86 180.4 4.000 0.02
7 19.09 nd* nd* -
10a 3814 nd* nd* -
Ethambutol 9.68 - - -
AZT - 0.0909 1122.58 12349.59
aSI: Selectivity index; *DNC: Did not converge to give IC50 values; #nd: not determined;.
Table 3. Docking scores for all synthesised quinoline-1,2,3-triazole-anilines against TB and HIV targets.
Table 3. Docking scores for all synthesised quinoline-1,2,3-triazole-anilines against TB and HIV targets.
Compound Docking Scores 4V1F Docking Scores 4MBS
11a -2.540 -6.990
11b -2.291 -6.729
11c -2.339 -6.899
11d -2.528 -7.561
11e -2.879 -7.371
11f -2.035 -4.815
11g -2.714 -6.427
11h -2.606 -7.362
11i -2.479 -5.825
11j -2.570 -5.301
Table 4. The electronic properties and global reactivity descriptors of 11h at the DFT/B3LYP/6-311++G(d,p) level of theory.
Table 4. The electronic properties and global reactivity descriptors of 11h at the DFT/B3LYP/6-311++G(d,p) level of theory.
Compound EHOMO (eV) ELUMO (eV) I (eV) A (eV) Eg (eV) η (eV) S (eV-1) χ (eV) ω (eV)
11h -5.89 -2.64 5.89 2.64 3.25 1.63 0.615 4.27 5.59
Table 5. In silico ADMET property predictions of 11a-j.
Table 5. In silico ADMET property predictions of 11a-j.
Compound QPlogKhsa QPlogS % Human oral absorption QPlogBB CNS #metab Ro5
11a 0.555 -5.804 100.000 -0.293 0 5 0
11b 0.697 -6.667 100.000 -0.127 0 4 0
11c 0.723 -6.793 100.000 -0.116 0 4 1
11d 0.597 -6.169 100.000 -0.186 0 4 0
11e 0.673 -6.548 100.000 -0.137 0 5 0
11f 0.549 -5.946 100.000 -0.329 0 6 0
11g 0.779 -6.922 100.000 -0.022 0 6 1
11h 0.598 -6.169 100.000 -0.187 0 6 0
11i 0.500 -5.932 88.989 -1.381 -2 6 0
11j 0.545 -5.938 100.000 -0.369 0 5 0
QPlogKhsa: prediction of binding to human serum albumin (-1.5 to 1.5); QplogS: Predicted aqueous solubility (-6.5 to 0.5); %Human oral absorption: Predicted human oral absorption on 0 to 100 % (>80% is high and <25% is poor); QplogBB: Predicted brain/blood partition coefficient (-3 to 12.0); CNS: Predicted central nervous system activity on a -2 (inactive) to +2 (active scale); #metab: Number of likely metabolic reactions (1 to 8); Ro5: Number of violation of Lipinski’s rule of five (Maximum is 4).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

50

Views

32

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated